AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph spanning from page 18, line 29 to page 19, line 13, as follows:

FIG. 5 shows changes in survival rate with the lapse of time of galactosamine-loaded mouse Escherichia coli inoculation model administered with a test substance (Reference Example B26) at various times, wherein the transverse axis shows the time after Escherichia coli inoculation and the vertical axis shows a survival rate (Survival (%)) of the mice, ● shows the result of administration of a solvent without a test substance immediately after Escherichia coli inoculation, ○ shows the result of administration of a test substance immediately after Escherichia coli inoculation, ⊕ shows the result of administration of a test substance at 0.5 hr after Escherichia coli inoculation, □ shows the result of administration of a test substance at 1 hr after Escherichia coli inoculation, Δ shows the result of administration of a test substance at 2 hr after ~~LPS~~ Escherichia coli inoculation, and ∇ shows the result of administration of a test substance at 4 hr after ~~LPS~~ Escherichia coli inoculation.

Please amend the paragraph on lines 3-24 of page 46 as follows:

(3) Ethyl 6-(benzylsulfonyl)-1-cyclohexene-1-carboxylate (compound 1'),
ethyl 6-[(4-methoxybenzyl)sulfonyl]-1-cyclohexene-1-carboxylate (compound 2'),
ethyl 6-[(2,4-difluorobenzyl)sulfonyl]-1-cyclohexene-1-carboxylate (compound 3'),
ethyl 6-[(2-chloro-4-fluorobenzyl)sulfonyl]-1-cyclohexene-1-carboxylate (compound 4'),
ethyl (-)-6-[(2-chloro-4-fluorobenzyl)sulfonyl]-1-cyclohexene-1-carboxylate (compound 5'),
ethyl (+)-6-[(2-chloro-4-fluorobenzyl)sulfonyl]-1-cyclohexene-1-carboxylate (compound 6'),
ethyl 3-[(2,4-difluorophenyl)sulfamoyl]-3,6-dihydro-2H-pyran-4-carboxylate (compound 7'),
and ethyl 3-[(2-chloro-4-fluorophenyl)sulfamoyl]-3,6-dihydro-2H-pyran-4-carboxylate (compound 8').
(4) Ethyl 6-[(2-chloro-4-fluorobenzyl)sulfonyl]-1-cyclohexene-1-carboxylate (compound 4'),
ethyl (+)-6-[(2-chloro-4-fluorobenzyl)sulfonyl]-1-cyclohexene-1-carboxylate (compound 6'),
and ethyl 3-[(2-chloro-4-fluorophenyl)sulfamoyl]-3,6-dihydro-2H-pyran-4-carboxylate (compound 8').

Please amend the paragraph at lines 4-22 on page 70 as follows:

When the combination agent of the present invention is administered, a cycloalkene compound or Compound A and a combination drug may be administered at the same time, or a combination drug may be administered first, and then the cycloalkene compound or Compound A may be administered. Alternatively, the cycloalkene compound or Compound A may be administered first, and then the combination drug may be administered. For time staggered administration, the time difference varies depending on the active ingredient to be administered, dosage form and administration route. For example, when a combination drug is to be administered first, the cycloalkene compound or Compound A is administered within 1 min-3 days, preferably 10 min-1 day, more preferably 15 min-1 hour, after the administration of the combination drug. When the cycloalkene compound or Compound A is to be administered first, the combination drug is administered within 1 min-1 day, preferably 10 min-6 hours, more preferably 15 min-1 hour, after the administration of the ~~combination drug~~ cycloalkene compound or compound A.